A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

NCT02954653 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to a change in sponsor prioritization.

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL: PF-06747143
DRUG: Cytarabine
DRUG: Daunorubicin
DRUG: Azacitidine
DRUG: Decitabine

Sponsor

Pfizer